| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.03. | Scibase Holding AB: Interim report | 93 | GlobeNewswire (Europe) | January 1 - December 31, 2025
The fourth quarter in figures
Net sales were TSEK 12,475 (8,598), +45%, cleared for currency effects +57%.
The loss after tax was TSEK 25,300 (21,677).
The loss per... ► Artikel lesen | |
| 10.03. | SciBase: New Study Positions Nevisense's EIS as a valuable and sensitive tool for assessing skin barrier impairment | 211 | PR Newswire | STOCKHOLM, March 10, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, is pleased to announce the publication... ► Artikel lesen | |
| 05.03. | SCIBASE: New Publication: US clinicians' real-world Nevisense experience improves melanoma detection | 3 | Cision News | ||
| 02.03. | SciBase receives approval by FDA for extended labelling in the US | 288 | PR Newswire | STOCKHOLM, March 2, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that it has received... ► Artikel lesen | |
| 02.03. | Scibase Holding AB: SciBase receives approval by FDA for extended labelling in the US | 152 | GlobeNewswire (Europe) | STOCKHOLM, Sweden - March 2, 2026 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, today announced that it has received approval... ► Artikel lesen | |
| 19.02. | SciBase's Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma | 260 | PR Newswire | STOCKHOLM, Feb. 19, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that Nevisense... ► Artikel lesen | |
| SCIBASE Aktie jetzt für 0€ handeln | |||||
| 17.02. | SCIBASE: A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns | 2 | Cision News | ||
| 17.02. | Scibase Holding AB: A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns | 502 | GlobeNewswire (Europe) | STOCKHOLM, Sweden - February 17, 2026 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, announces that results from a new study will... ► Artikel lesen | |
| 06.02. | SciBase: Recalculation of warrants of series TO 2 following rights issue and updated last day of trading in BTA from the rights issue | 293 | PR Newswire | STOCKHOLM, Feb. 6, 2026 /PRNewswire/ -- In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April... ► Artikel lesen | |
| 27.01. | SciBase announces final outcome of the rights issue and the resolution on a set-off issue within the framework of the offer to repurchase outstanding warrants of series TO 2 | 325 | PR Newswire | STOCKHOLM, Jan. 27, 2026 /PRNewswire/ -- SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the final outcome of the rights issue of shares resolved by the Company on... ► Artikel lesen | |
| 27.01. | Scibase Holding AB: SciBase announces final outcome of the rights issue and the resolution on a set-off issue within the framework of the offer to repurchase outstanding warrants of series TO 2 | 158 | GlobeNewswire (Europe) | SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the final outcome of the rights issue of shares resolved by the Company on 29 December 2025 (the "Rights Issue"). The Rights Issue... ► Artikel lesen | |
| 26.01. | SciBase: Change of date for publication of the year-end report for the financial year 2025 | 269 | PR Newswire | STOCKHOLM, Jan. 26, 2026 /PRNewswire/ -- The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has resolved to postpone the publication of the year-end report for... ► Artikel lesen | |
| 22.01. | Increased commitment in SciBase rights issue | 242 | PR Newswire | STOCKHOLM, Jan. 22, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, announces it has been informed... ► Artikel lesen | |
| 09.01. | SciBase publishes information document regarding rights issue | 389 | PR Newswire | STOCKHOLM, Jan. 9, 2026 /PRNewswire/ -- The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") publishes information documents in connection with the rights issue... ► Artikel lesen | |
| 09.01. | SciBase announces outcome of the offer to repurchase outstanding warrants of series TO 2 | 337 | PR Newswire | STOCKHOLM, Jan. 9, 2026 /PRNewswire/ -- SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome of the repurchase offer for all warrants of series TO 2 resolved... ► Artikel lesen | |
| 06.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.01.2026 | 507 | Xetra Newsboard | Das Instrument NW1 SE0017131865 WINDON ENERGY GROUP AB EQUITY wird cum Kapitalmassnahme gehandelt am 06.01.2026 und ex Kapitalmassnahme am 07.01.2026 The instrument NW1 SE0017131865 WINDON ENERGY GROUP... ► Artikel lesen | |
| 29.12.25 | The Board of Directors of SciBase resolves on a previously communicated rights issue of shares of approximately SEK 83 million | 762 | PR Newswire | STOCKHOLM, Dec. 29, 2025 /PRNewswire/ -- The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, based on the authorization granted by the Annual General... ► Artikel lesen | |
| 11.12.25 | SciBase Expands Its Intellectual Property Portfolio to include the analysis of the epithelial skin barrier with New European Patent | 349 | PR Newswire | STOCKHOLM, Dec. 11, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, announces that it has been granted... ► Artikel lesen | |
| 05.12.25 | SciBase publishes information document regarding the offer to repurchase outstanding warrants of series TO 2 | 473 | PR Newswire | STOCKHOLM, Dec. 5, 2025 /PRNewswire/ -- SciBase Holding AB (publ) ("SciBase" or the "Company") publishes an information document in connection with the offer to repurchase all outstanding... ► Artikel lesen | |
| 05.12.25 | Bulletin from the extraordinary general meeting in SciBase Holding AB (publ) | 295 | PR Newswire | STOCKHOLM, Dec. 5, 2025 /PRNewswire/ -- Today, an extraordinary general meeting has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ROKU | 80,33 | -0,52 % | Roku's ad-free streaming service was already a great deal - now it's adding Disney movies | ||
| SERNOVA BIOTHERAPEUTICS | 0,098 | -0,51 % | Sernova Biotherapeutics Inc: Sernova says Swetlow fired over trip, improper payouts | ||
| BOSTON SCIENTIFIC | 60,60 | -1,62 % | Truist senkt Kursziel für Boston Scientific wegen Bewertung | ||
| PAUL HARTMANN | 215,00 | +0,47 % | PAUL HARTMANN schließt Geschäftsjahr 2025 mit Umsatz- und Ergebnissteigerung ab | Heidenheim (ots) - - Organisches Umsatzwachstum beträgt 2,2 %; Umsatzerlöse betragen 2.449,6 Mio. EUR - Bereinigtes EBITDA steigt um 15,5 Mio. EUR gegenüber Vorjahr auf 276,9 Mio. EUR - Transformationsprogramm... ► Artikel lesen | |
| SYSMEX | 7,700 | +1,32 % | Sysmex Corporation Bottom Line Drops In Nine Months | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) announced a profit for nine months that Dropped, from the same period last yearThe company's earnings came in at JPY33.694 billion, or JPY54.05... ► Artikel lesen | |
| ADDLIFE | 12,750 | -1,47 % | AddLife AB: AddLife acquires BioSpectrum Ltd | AddLife acquires BioSpectrum Ltd, a fast-growing distributor of surgical solutions in the fields of urology, gynaecology and general surgery in the UK. The company will be included within AddLife's... ► Artikel lesen | |
| EMBECTA | 7,800 | +1,30 % | Embecta Corp.: embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited | PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("Embecta") (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has entered into a definitive agreement... ► Artikel lesen | |
| ENOVIS | 19,200 | +1,59 % | Enovis Corporation: Update: Enovis Announces Fourth Quarter and Full Year 2025 Results | Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic... ► Artikel lesen | |
| PULMONX | 1,180 | -7,09 % | Pulmonx Corporation: Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results | REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported... ► Artikel lesen | |
| KOOTH | 1,250 | 0,00 % | Kooth PLC - Notice of Full Year Results | ||
| REVITALIST LIFESTYLE AND WELLNESS | 0,015 | -100,00 % | Revitalist Lifestyle and Wellness Ltd: Revitalist Lifestyle CEO Walker, CFO Murray resign | ||
| BACTIGUARD | 1,360 | +2,64 % | Bactiguard Holding AB: Bactiguard Holding AB's year-end report 2025 | A year of strategic execution concluded with a strong Q4
Fourth quarter 2025 (October - December)
Total revenue amounted to SEK 65.6 (68.3) million, a decrease of SEK 2.7 million corresponding to... ► Artikel lesen | |
| SI-BONE | 10,700 | -2,73 % | Smith & Nephew Plc: Smith+Nephew signs distribution agreement with SI-BONE | Trauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global... ► Artikel lesen | |
| PEIJIA MEDICAL | 0,590 | -4,06 % | PEIJIA-B (09996): VOLUNTARY ANNOUNCEMENT - DCWIRE MICRO GUIDEWIRE RECEIVES FDA 510(K) CLEARANCE | ||
| LIFECARE ASA | 0,033 | 0,00 % | Lifecare ASA: Financial calendar |